Advaxis licenses ISG15 tumor antigen from University of Pennsylvania Advaxis, Inc., , a head in developing another era of immunotherapies for tumor and infectious illnesses, has specifically licensed the use of antigen ISG15 in Advaxis’ Lm-LLO centered immunotherapies from the University of Pennsylvania. This intellectual property resulted from research conducted in Dr. Yvonne Paterson’s laboratory that demonstrated ISG15 was an effective immunological focus on for the treating breast cancer in animal models.APP’s Imipenem and Cilastatin for Injection will be accessible in 250 mg and 500 mg single dose vials, while Meropenem for Injection will be accessible in 500 mg and 1 gram single dosage vials. Both products are AP-rated, bar-coded and preservative-free. According to IMS Health, in 2011 combined product sales of both products in the usa were around $229 million. The forthcoming launch of these two products marks APP’s entry in to the Carbapenem market, said John Ducker, Chief and President Executive Officer of APP Pharmaceuticals. Adding these two products to your portfolio further strengthens our existing anti-infective series and helps solidify our continuing leadership in the dependable way to obtain sterile generic injectables.